Biomoda, Inc. of Albuquerque, NM, maker of early lung cancer detection testing and other cancer diagnostic technology, announced today that its common stock has begun trading on the OTC Bulletin Board under the ticker symbol “BMOD”. Biomoda‘s technology is based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells that are extracted from lung sputum samples. Cancerous cells glow red under fluorescent light to allow detection under a microscope. The patented technology, a non-invasive cytology based assay, is amenable to use by automated sample reading equipment platforms. This will allow large populations to be screened for cancer at a reasonable cost with high specificity and greater sensitivity and accuracy than most other types of cancer screening.